Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 25.7.2015 | EN | Official Journal of the European Union | L 197/10 |

---

COMMISSION REGULATION (EU) 2015/1221

of 24 July 2015

amending Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures, for the purposes of its adaptation to technical and scientific progress

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 [(1)](#ntr1-L_2015197EN.01001001-E0001), and in particular Article 37(5) thereof,

Whereas:

|  |  |
| --- | --- |
| (1) | Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains two lists of harmonised classification and labelling of hazardous substances. Table 3.1 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to Regulation (EC) No 1272/2008. Table 3.2 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Annex VI to Council Directive 67/548/EEC [(2)](#ntr2-L_2015197EN.01001001-E0002). |

|  |  |
| --- | --- |
| (2) | Proposals for new or updated harmonised classification and labelling of certain substances have been submitted to the European Chemicals Agency (ECHA) pursuant to Article 37 of Regulation (EC) No 1272/2008. Based on the opinions on those proposals issued by the Committee for Risk Assessment of ECHA, as well as on the comments received from the parties concerned, it is appropriate to introduce or update harmonised classification and labelling of certain substances by amending Annex VI to that Regulation. |

|  |  |
| --- | --- |
| (3) | With regard to the substance nitric acid … % (EC number: 231-714-2), new scientific data has been made available for the hazard class ‘acute toxicity’ which suggests that the classification for this hazard class as recommended in the RAC opinion, which is based on older data, might not be appropriate. Therefore, this hazard class should not be included in Annex VI to Regulation (EC) No 1272/2008 until RAC has issued an opinion on the new information, while all other classes covered by the earlier opinion should be included. |

|  |  |
| --- | --- |
| (4) | With regard to the substance phenol, dodecyl-, branched (EC number: 310-154-3), the RAC is in the process of adopting a new opinion for the specific concentration limits to be applied to the hazard class ‘toxic for reproduction’. Therefore, this hazard class should not be included in Annex VI to Regulation (EC) No 1272/2008 until that opinion is finalised. |

|  |  |
| --- | --- |
| (5) | Compliance with the new harmonised classifications should not be required immediately, as a certain period of time will be necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new classifications and to sell existing stocks. In addition, a certain period of time will be necessary to allow suppliers to comply with the registration obligations resulting from the new harmonised classifications for substances classified as carcinogenic, mutagenic or toxic to reproduction, categories 1A and 1B (Table 3.1) and categories 1 and 2 (Table 3.2), or as very toxic to aquatic organisms which may cause long term effects in the aquatic environment, in particular with those set out in Article 23 of Regulation (EC) No 1907/2006 of the European Parliament and of the Council [(3)](#ntr3-L_2015197EN.01001001-E0003). |

|  |  |
| --- | --- |
| (6) | In line with the transitional provisions of Regulation (EC) No 1272/2008 which allow the application of the new provisions at an earlier stage on a voluntary basis, suppliers should have the possibility of applying the new harmonised classifications and of adapting the labelling and packaging accordingly on a voluntary basis before the deadline for compliance. |

|  |  |
| --- | --- |
| (7) | The measures provided for in this Regulation are in accordance with the opinion of the Committee established under Article 133 of Regulation (EC) No 1907/2006, |

HAS ADOPTED THIS REGULATION:

Article 1

Annex VI to Regulation (EC) No 1272/2008 is amended in accordance with the Annex to this Regulation.

Article 2

By way of derogation from Article 3(2), the harmonised classifications set out in Annex to this Regulation may be applied before the date referred to in Article 3(2).

Article 3

1.   This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

2.   Article 1 shall apply in respect of substances and mixtures from 1 January 2017.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 24 July 2015.

For the Commission

The President

Jean-Claude JUNCKER

---

---

ANNEX

Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| (1) | Table 3.1 is amended as follows:   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | (a) | the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:   |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Index No | International Chemical Identification | EC No | CAS No | Classification | | Labelling | | | Specific Conc. Limits, M-factors | Notes | | Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) | | 007-004-00-1 | nitric acid … % | 231-714-2 | 7697-37-2 | Ox. Liq. 2  Skin Corr. 1A | H272  H314 | GHS03  GHS05  Dgr | H272  H314 | EUH071 | Skin Corr. 1A; H314: C ≥ 20 %  Skin Corr. 1B; H314: 5 % ≤ C < 20 %  Ox. Liq. 2; H272: C ≥ 99 %  Ox. Liq. 3; H272: 99 % > C ≥ 65 % | B | | 015-003-00-2 | calcium phosphide; tricalcium diphosphide | 215-142-0 | 1305-99-3 | Water-react. 1  Acute Tox. 2  Acute Tox. 3  Acute Tox. 1  Eye Dam. 1  Aquatic Acute 1 | H260  H300  H311  H330  H318  H400 | GHS02  GHS06  GHS05  GHS09  Dgr | H260  H300  H311  H330  H318  H400 | EUH029  EUH032 | M = 100 |  | | 031-001-00-4 | gallium arsenide | 215-114-8 | 1303-00-0 | Repr. 1B  Carc. 1B  STOT RE 1 | H360F  H350  H372 (respiratory and haematopoietic systems) | GHS08  Dgr | H360F  H350  H372 (respiratory and haematopoietic systems) |  |  |  | | 050-008-00-3 | tributyltin compounds, with the exception of those specified elsewhere in this annex | — | — | Repr. 1B  Acute Tox. 3  Acute Tox. 4\*  STOT RE 1  Skin Irrit. 2  Eye Irrit. 2  Aquatic Acute 1  Aquatic Chronic 1 | H360FD  H301  H312  H372\*\*  H315  H319  H400  H410 | GHS08  GHS06  GHS09  Dgr | H360FD  H301  H312  H372\*\*  H315  H319  H410 |  | \*  STOT RE 1; H372: C ≥ 1 %  STOT RE 2; H373: 0,25 % ≤ C < 1 %  Skin Irrit. 2; H315:C ≥ 1 %  Eye Irrit. 2; H319:C ≥ 1 %  M = 10 | A  1 | | 603-102-00-9 | 1,2-epoxybutane | 203-438-2 | 106-88-7 | Flam. Liq. 2  Carc. 2  Acute Tox. 4\*  Acute Tox. 4\*  Acute Tox. 4\*  STOT SE 3  Skin Irrit. 2  Eye Irrit. 2 | H225  H351  H302  H312  H332  H335  H315  H319 | GHS02  GHS08  GHS07  Dgr | H225  H351  H302  H312  H332  H335  H315  H319 |  |  |  | | 603-197-00-7 | tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol | 403-640-2 | 107534-96-3 | Repr. 2  Acute Tox. 4  Aquatic Acute 1  Aquatic Chronic 1 | H361d\*\*\*  H302  H400  H410 | GHS08  GHS07  GHS09  Wng | H361d\*\*\*  H302  H410 |  | M = 1  M = 10 |  | | 606-054-00-7 | isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α,α,α-trifluoro-2-mesyl-p-tolyl ketone | — | 141112-29-0 | Repr. 2  Aquatic Acute 1  Aquatic Chronic 1 | H361d\*\*\*  H400  H410 | GHS08  GHS09  Wng | H361d\*\*\*  H410 |  | M = 10  M = 100 |  | | 607-197-00-8 | nonanoic acid | 203-931-2 | 112-05-0 | Skin Irrit. 2  Eye Irrit. 2  Aquatic Chronic 3 | H315  H319  H412 | GHS07  Wng | H315  H319  H412 |  |  |  | | 613-042-00-5 | imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole | 252-615-0 | 35554-44-0 | Carc. 2  Acute Tox. 3  Acute Tox. 4  Eye Dam. 1  Aquatic Chronic 1 | H351  H301  H332  H318  H410 | GHS08  GHS06  GHS05  GHS09  Dgr | H351  H301  H332  H318  H410 |  | M = 10 |  | | 613-057-00-7 | dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine | 216-474-9 | 1593-77-7 | Repr. 2  STOT RE 2  Skin Corr. 1C  Skin Sens. 1A  Aquatic Acute 1  Aquatic Chronic 1 | H361d  H373 (liver)  H314  H317  H400  H410 | GHS08  GHS05  GHS07  GHS09  Dgr | H361d  H373 (liver)  H314  H317  H410 | EUH071 | M = 1  M = 1 |  | | 613-133-00-X | etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole | 219-991-8 | 2593-15-9 | Carc. 2  Acute Tox. 4  Skin Sens. 1  Aquatic Acute 1  Aquatic Chronic 1 | H351  H302  H317  H400  H410 | GHS08  GHS07  GHS09  Wng | H351  H302  H317  H410 |  | M = 1  M = 1 |  | | 613-149-00-7 | pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one | 405-700-3 | 96489-71-3 | Acute Tox. 3  Acute Tox. 3  Aquatic Acute 1  Aquatic Chronic 1 | H331  H301  H400  H410 | GHS06  GHS09  Dgr | H331  H301  H410 |  | M = 1 000  M = 1 000 |  | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | (b) | the following entries are inserted in accordance with the order of the entries set out in Table 3.1:   |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Index No | International Chemical Identification | EC No | CAS No | Classification | | Labelling | | | Specific Conc. Limits, M-factors | Notes | | Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) | | 019-003-00-3 | potassium (E,E)-hexa-2,4-dienoate | 246-376-1 | 24634-61-5 | Eye Irrit. 2 | H319 | GSH07  Wng | H319 |  |  |  | | 604-092-00-9 | phenol, dodecyl-, branched [1];  phenol, 2-dodecyl-, branched;  phenol, 3-dodecyl-, branched;  phenol, 4-dodecyl-, branched;  phenol, (tetrapropenyl) derivatives [2] | 310-154-3 [1] | 121158-58-5 [1]  74499-35-7 [2] | Skin Corr. 1C  Aquatic Acute 1  Aquatic Chronic 1 | H314  H400  H410 | GHS05  GHS09  Dgr | H314  H410 |  | M = 10  M = 10 |  | | 606-148-00-8 | carvone (ISO);  2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1]  d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2]  l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3] | 202-759-5 [1]  218-827-2 [2]  229-352-5 [3] | 99-49-0 [1]  2244-16-8 [2]  6485-40-1 [3] | Skin Sens. 1 | H317 | GHS07  Wng | H317 |  |  |  | | 606-149-00-3 | tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione | — | 335104-84-2 | Repr. 2  STOT RE 2  Skin Sens. 1  Aquatic Acute 1  Aquatic Chronic 1 | H361d  H373 (eyes, kidneys, liver)  H317  H400  H410 | GHS08  GHS07  GHS09  Wng | H361d  H373 (eyes, kidneys, liver)  H317  H410 |  | M = 100  M = 10 |  | | 607-707-00-9 | fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate | — | 71283-80-2 | STOT RE 2  Skin Sens. 1  Aquatic Acute 1  Aquatic Chronic 1 | H373 (kidneys)  H317  H400  H410 | GHS08  GHS07  GHS09  Wng | H373 (kidneys)  H317  H410 |  | M = 1  M = 1 |  | | 607-708-00-4 | octanoic acid | 204-677-5 | 124-07-2 | Skin Corr. 1C  Aquatic Chronic 3 | H314  H412 | GHS05  Dgr | H314  H412 |  |  |  | | 607-709-00-X | decanoic acid | 206-376-4 | 334-48-5 | Skin Irrit. 2  Eye Irrit. 2  Aquatic Chronic 3 | H315  H319  H412 | GHS07  Wng | H315  H319  H412 |  |  |  | | 607-710-00-5 | 1,2-benzenedicarboxylic acid, dihexyl ester, branched and linear | 271-093-5 | 68515-50-4 | Repr. 1B | H360FD | GHS08  Dgr | H360FD |  |  |  | | 607-711-00-0 | spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate | — | 203313-25-1 | Repr. 2  STOT SE 3  Eye Irrit. 2  Skin Sens. 1A  Aquatic Acute 1  Aquatic Chronic 1 | H361fd  H335  H319  H317  H400  H410 | GHS08  GHS07  GHS09  Wng | H361fd  H335  H319  H317  H410 |  | M = 1  M = 1 |  | | 607-712-00-6 | dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate | 250-778-2 | 31717-87-0 | Repr. 2  STOT RE 2  Skin Corr. 1C  Skin Sens. 1A  Aquatic Chronic 1 | H361d  H373 (liver)  H314  H317  H410 | GHS08  GHS05  GHS07  GHS09  Dgr | H361d  H373 (liver)  H314  H317  H410 | EUH071 | M = 1 |  | | 607-713-00-1 | fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate | — | 134098-61-6 | Acute Tox. 3  Acute Tox. 2  Skin Sens. 1B  Aquatic Acute 1  Aquatic Chronic 1 | H301  H330  H317  H400  H410 | GHS06 GHS09  Dgr | H301  H330  H317  H410 |  | M = 100  M = 1 000 |  | | 607-714-00-7 | triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate | — | 126535-15-7 | Carc. 2  Aquatic Acute 1  Aquatic Chronic 1 | H351  H400  H410 | GHS08  GHS09  Wng | H351  H410 |  | M = 100  M = 10 |  | | 607-715-00-2 | bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate | 442-820-5 | 149877-41-8 | STOT RE 2  Skin Sens. 1  Aquatic Acute 1  Aquatic Chronic 1 | H373  H317  H400  H410 | GHS08  GHS07  GHS09  Wng | H373  H317  H410 |  | M = 1  M = 1 |  | | 613-319-00-0 | imidazole | 206-019-2 | 288-32-4 | Repr. 1B  Acute Tox. 4  Skin Corr. 1C | H360D  H302  H314 | GHS08  GHS07  GHS05  Dgr | H360D  H302  H314 |  |  |  | | 613-320-00-6 | lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione | 218-499-0 | 2164-08-1 | Carc. 2  Aquatic Acute 1  Aquatic Chronic 1 | H351  H400  H410 | GHS08  GHS09  Wng | H351  H410 |  | M = 10  M = 10 |  | | 616-213-00-2 | mandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide | — | 374726-62-2 | Aquatic Acute 1  Aquatic Chronic 1 | H400  H410 | GHS09  Wng | H410 |  | M = 1  M = 1 |  | | 616-214-00-8 | metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide | — | 139528-85-1 | Carc. 2  STOT RE 2  Aquatic Acute 1  Aquatic Chronic 1 | H351  H373 (eyes, kidneys)  H400  H410 | GHS08  GHS09  Wng | H351  H373 (eyes, kidneys)  H410 |  | M = 1 000  M = 100 |  | | 616-215-00-3 | dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide | — | 163515-14-8 | Acute Tox. 4  Skin Sens. 1  Aquatic Acute 1  Aquatic Chronic 1 | H302  H317  H400  H410 | GHS07  GHS09  Wng | H302  H317  H410 |  | M = 10  M = 10 |  | | 616-216-00-9 | flonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide | — | 158062-67-0 | Acute Tox. 4 | H302 | GHS07  Wng | H302 |  |  |  | | 616-217-00-4 | sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide | — | 946578-00-3 | Acute Tox. 4  Aquatic Acute 1  Aquatic Chronic 1 | H302  H400  H410 | GHS07  GHS09  Wng | H302  H410 |  | M = 1  M = 1 |  | | |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| (2) | Table 3.2 is amended as follows:   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | (a) | the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:   |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | | Index No | International Chemical Identification | EC No | CAS No | Classification | Labelling | Concentration Limits | Notes | | 007-004-00-1 | nitric acid … % | 231-714-2 | 7697-37-2 | O; R8  C; R35 | O; C  R: 8-35  S: (1/2-)26-28- 36/37/39-45-63 | O; R8: C ≥ 65 %  C; R35: C ≥ 20 %  C; R34: 5 % ≤ C < 20 % | B | | 015-003-00-2 | calcium phosphide; tricalcium diphosphide | 215-142-0 | 1305-99-3 | F; R15/29  T+; R26/28  Xn; R21  R32  Xi; R38-41  N; R50 | F; T+; N  R: 15/29-21-26/28-32-38-41-50  S:(1/2-)26-28-30-36/37/39-43-45-60-61 | N; R50: C ≥ 0,25 % |  | | 031-001-00-4 | gallium arsenide | 215-114-8 | 1303-00-0 | Repr. Cat. 2; R60  Carc. Cat. 2; R45  T; R48/23 | T  R: 45-48/23-60  S: 45-53 |  | E | | 050-008-00-3 | tributyltin compounds, with the exception of those specified elsewhere in this annex | — | — | Repr. Cat. 2; R60-61  T; R25-48/23/25  Xn; R21  Xi; R36/38  N; R50-53 | T; N  R: 21-25-36/38-48/23/25-50/53-60-61  S: 45-53-60-61 | T; R25: C ≥ 2,5 %  Xn; R22: 0,25 % ≤ C < 2,5 %  Xn: R21: C ≥ 1 %  T; R48/23/25: C ≥ 1 %  Xn; R48/20/22: 0,25 % ≤ C < 1 %  Xi; R36/38: C ≥ 1 %  N; R50-53: C ≥ 2,5 %  N; R51-53: 0,25 % ≤ C < 2,5 %  R52-53: 0,025 % ≤ C < 0,25 % | A  1 | | 603-102-00-9 | 1,2-epoxybutane | 203-438-2 | 106-88-7 | F; R11  Carc. Cat. 3; R40  Xn; R20/21/22  Xi; R36/37/38 | F; Xn  R: 11-20/21/22-36/37/38-40-  S: (2-)9-16-29-36/37-46 |  |  | | 603-197-00-7 | tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol | 403-640-2 | 107534-96-3 | Repr. Cat. 3; R63  Xn; R22  N; R50-53 | Xn; N  R: 22-50/53-63  S: (2-)22-36/37-60-61 | N; R50-53: C ≥ 25 %  N; R51-53: 2,5 % ≤ C <25 %  R52-53: 0,25 % ≤ C < 2,5 % |  | | 606-054-00-7 | isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α, α,α-trifluoro-2-mesyl-p-tolyl ketone | — | 141112-29-0 | Repr. Cat. 3; R63  N; R50-53 | Xn; N  R: 50/53-63  S: (2-)36/37-60-61 | N; R50-53: C ≥ 2,5 %  N; R51-53: 0,25 % ≤ C < 2,5 %  R52-53: 0,025 % ≤ C < 0,25 % |  | | 607-197-00-8 | nonanoic acid | 203-931-2 | 112-05-0 | Xi; R36/38  N; R51-53 | Xi; N  R: 36/38-51/53  S: (2-)46-61 |  |  | | 613-042-00-5 | imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole | 252-615-0 | 35554-44-0 | Carc. Cat. 3; R40  Xn; R20/22  Xi; R41  N; R51-53 | Xn; N  R: 20/22-40-41-51/53  S: (2-)26-36/37/39-46-61 |  |  | | 613-057-00-7 | dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine | 216-474-9 | 1593-77-7 | Repr. Cat. 3; R63  C; R34  R43  N; R50-53 | C; N  R: 34-43-50/53-63  S: (1/2-)26-28-36/37/39-45-60-61 | C; R34: C ≥ 10 %  Xi; R36/37/38: 5 % ≤ C < 10 %  N; R50-53: C ≥ 25 %  N; R51-53: 2,5 % ≤ C < 25 %  R52-53: 0,25 % ≤ C < 2,5 % |  | | 613-133-00-X | etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole | 219-991-8 | 2593-15-9 | Carc. Cat. 3; R40  Xn; R22  R43  N; R50-53 | Xn; N  R: 22-40-43-50/53  S: (2-)36/37-46-60-61 | N; R50-53: C ≥ 25 %  N; R51-53: 2,5 % ≤ C < 25 %  R52-53: 0,25 % ≤ C < 2,5 % |  | | 613-149-00-7 | pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one | 405-700-3 | 96489-71-3 | T; R23/25  N; R50-53 | T; N  R: 23/25-50/53  S: (1/2-)36/37-45-60-61 | N; R50-53: C ≥ 0,025 %  N; R51-53: 0,0025 % ≤ C < 0,025 %  R52-53: 0,00025 % ≤ C < 0,0025 % |  | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | (b) | the following entries are inserted in accordance with the order of the entries set out in Table 3.2:   |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | | Index No | International Chemical Identification | EC No | CAS No | Classification | Labelling | Concentration Limits | Notes | | 019-003-00-3 | potassium (E,E)-hexa-2,4-dienoate | 246-376-1 | 24634-61-5 | Xi; R36 | Xi  R: 36  S: (2-)25-46 |  |  | | 604-092-00-9 | phenol, dodecyl-, branched [1];  phenol, 2-dodecyl-, branched;  phenol, 3-dodecyl-, branched;  phenol, 4-dodecyl-, branched;  phenol, (tetrapropenyl) derivatives [2] | 310-154-3 [1]-[2] | 121158-58-5 [1]  74499-35-7 [2] | C; R34  N; R50-53 | C; N  R: 34-50/53  S: (1/2-)26-36/37/39-45-61 | N; R50-53: C ≥ 2,5 %  N; R51-53: 0,25 % ≤ C < 2,5 %  R52-53: 0,025 % ≤ C < 0,25 % |  | | 606-148-00-8 | carvone (ISO);  2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1]  d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2]  l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3] | 202-759-5 [1]  218-827-2 [2]  229-352-5 [3] | 99-49-0 [1]  2244-16-8 [2]  6485-40-1 [3] | R43 | Xi  R: 43  S: (2-)24-37 |  |  | | 606-149-00-3 | tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione |  | 335104-84-2 | Repr. Cat. 3; R63  Xn; R48/22  R43  N; R50-53 | Xn; N  R: 43-48/22-50/53-63  S: (2-)36/37-46-60-61 | N; R50-53: C ≥ 0,25 %  N; R51-53: 0,025 % ≤ C < 0,25 %  R52-53: 0,0025 % ≤ C < 0,025 % |  | | 607-707-00-9 | fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate | — | 71283-80-2 | Xn; R48/22  R43  N; R50-53 | Xn; N  R: 43-48/22-50/53  S: (2-)24-37-46-60-61 | N; R50-53: C ≥ 25 %  N; R51-53: 2,5 % ≤ C < 25 %  R52-53: 0,25 % ≤ C < 2,5 % |  | | 607-708-00-4 | octanoic acid | 204-677-5 | 124-07-2 | C; R34  N; R51-53 | C; N  R: 34-51/53  S: (1/2-)26-36/37/39-45-61 |  |  | | 607-709-00-X | decanoic acid | 206-376-4 | 334-48-5 | Xi; R36/38  N; R51-53 | Xi; N  R: 36/38-51/53  S: (2-)25-46-61 |  |  | | 607-710-00-5 | 1,2-Benzenedicarboxylic acid, dihexyl ester, branched and linear | 271-093-5 | 68515-50-4 | Repr. Cat. 2; R60-61 | T  R: 60-61  S: 53-45 |  |  | | 607-711-00-0 | spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate | — | 203313-25-1 | Repr. Cat. 3; R62-63  Xi; R36/37  R43  N; R50-53 | Xn; N  R: 36/37-43-50/53-62-63  S: (2-)36/37-60-61 | Xi; R43: C ≥ 0,1 %  N; R50-53: C ≥ 25 %  N; R51-53: 2,5 % ≤ C < 25 %  R52-53: 0,25 % ≤ C < 2,5 % |  | | 607-712-00-6 | dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate | 250-778-2 | 31717-87-0 | Repr. Cat. 3; R63  C; R34  R43  N; R51-53 | C; N  R: 34-43-51/53-63  S: (1/2-)26-28-36/37/39-45-61 | C; R34: C ≥ 10 %  Xi: R36/37/38: 5 % ≤ C < 10 % |  | | 607-713-00-1 | fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate | — | 134098-61-6 | T+; R26  Xn; R22  R43  N; R50-53 | T+; N  R: 22-26-43-50/53  S: (1/2-)28-36/37-45-60-61-63 | N; R50-53: C ≥ 0,25 %  N; R51-53: 0,025 % ≤ C < 0,25 %  R52-53: 0,0025 % ≤ C < 0,025 % |  | | 607-714-00-7 | triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate | — | 126535-15-7 | Carc. Cat. 3; R40  N; R50-53 | Xn; N  R: 40-50/53  S: (2-)36/37-60-61 | N; R50-53: C ≥ 0,25 %  N; R51-53: 0,025 % ≤ C < 0,25 %  R52-53: 0,0025 % ≤ C < 0,025 % |  | | 607-715-00-2 | bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate | 442-820-5 | 149877-41-8 | R43  N; R50-53 | Xi; N  R: 43-50/53  S: (2-)24-37-60-61 | N; R50-53: C ≥ 25 %  N; R51-53: 2,5 % ≤ C < 25 %  R52-53: 0,25 % ≤ C < 2,5 % |  | | 613-319-00-0 | imidazole | 206-019-2 | 288-32-4 | Repr. Cat 2; R61  Xn; R22  C; R34 | T; C  R: 22-34-61  S: 53-45 |  |  | | 613-320-00-6 | lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione | 218-499-0 | 2164-08-1 | Carc. Cat. 3; R40  N; R50-53 | Xn; N  R: 40-50/53  S: (2-)36/37-60-61 | N; R50-53: C ≥ 2,5 %  N; R51-53: 0,25 % ≤ C < 2,5 %  R52-53: 0,025 % ≤ C < 0,25 % |  | | 616-213-00-2 | mandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide | — | 374726-62-2 | N; R50-53 | N  R: 50/53  S: 60-61 | N; R50-53: C ≥ 25 %  N; R51-53: 2,5 % ≤ C <25 %  R52-53: 0,25 % ≤ C < 2,5 % |  | | 616-214-00-8 | metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide | — | 139528-85-1 | Carc. Cat. 3; R40  Xn; R48/22  N; R50-53 | Xn; N  R: 40-48/22-50/53  S: (2-)36/37-46-60-61 | N; R50-53: C ≥ 0,025 %  N; R51-53: 0,0025 % ≤ C < 0,025 %  R52/53: 0,00025 % ≤ C < 0,0025 % |  | | 616-215-00-3 | dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide | — | 163515-14-8 | Xn; R22  R43  N; R50-53 | Xn; N  R: 22-43-50/53  S: (2-)24-37-60-61 | N; R50-53: C ≥ 2,5 %  N; R51-53: 0,25 % ≤ C < 2,5 %  R52-53: 0,025 % ≤ C < 0,25 % |  | | 616-216-00-9 | flonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide | — | 158062-67-0 | Xn; R22 | Xn  R: 22  S: (2-)46 |  |  | | 616-217-00-4 | sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide | — | 946578-00-3 | Xn; R22  N; R50-53 | Xn; N  R: 22-50/53  S: (2-)60-61 | N; R50-53: C ≥ 25 %  N; R51-53: 2,5 % ≤ C < 25 %  R52-53: 0,25 % ≤ C < 2,5 % |  | | |

---

[Top](#document1)